Cost-effectiveness of ancrod treatment of acute ischaemic stroke: Results from the Stroke Treatment with Ancrod Trial (STAT)

Journal of Evaluation in Clinical Practice

Volumn 8, Issue 1, 2002, Pages 61-70

  Samsa, Gregory P ^a,b   Matchar, David B ^a,b   Williams, G Rhys ^c   Levy, David E ^c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Ancrod; Cost effectiveness analysis; Decision modelling; Ischaemic stroke; Randomized trial; Simulation modelling

Indexed keywords

ANCROD; PLACEBO;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIMULATION;

ADULT; ANCROD; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RISK;

EID: 0036121634     PISSN: 13561294     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2753.2002.00315.x     Document Type: Article

References (0)